{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T05:46:15Z","timestamp":1790401575998,"version":"4.1.0"},"reference-count":53,"publisher":"F1000 Research Ltd","license":[{"start":{"date-parts":[[2018,9,3]],"date-time":"2018-09-03T00:00:00Z","timestamp":1535932800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["f1000research.com"],"crossmark-restriction":false},"short-container-title":["F1000Res"],"abstract":"<ns4:p>The intestinal apicomplexan parasite <ns4:italic>Cryptosporidium<\/ns4:italic> is a major cause of diarrheal disease in humans worldwide. However, treatment options are severely limited. The search for novel interventions is imperative, yet there are several challenges to drug development, including intractability of the parasite and limited technical tools to study it. This review addresses recent, exciting breakthroughs in this field, including novel cell culture models, strategies for genetic manipulation, transcriptomics, and promising new drug candidates. These advances will stimulate the ongoing quest to understand <ns4:italic>Cryptosporidium<\/ns4:italic> and the pathogenesis of cryptosporidiosis and to develop new approaches to combat this disease.<\/ns4:p>","DOI":"10.12688\/f1000research.15333.1","type":"journal-article","created":{"date-parts":[[2018,9,3]],"date-time":"2018-09-03T09:35:12Z","timestamp":1535967312000},"page":"1380","update-policy":"https:\/\/doi.org\/10.12688\/f1000research.crossmark-policy","source":"Crossref","is-referenced-by-count":42,"title":["Recent Breakthroughs and Ongoing Limitations in Cryptosporidium Research"],"prefix":"10.12688","volume":"7","author":[{"given":"Seema","family":"Bhalchandra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daviel","family":"Cardenas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9093-1698","authenticated-orcid":false,"given":"Honorine D.","family":"Ward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2560","published-online":{"date-parts":[[2018,9,3]]},"reference":[{"key":"ref-1","doi-asserted-by":"publisher","first-page":"85-94","DOI":"10.1016\/S1473-3099(14)70772-8","article-title":"A review of the global burden, novel diagnostics, therapeutics, and vaccine targets for cryptosporidium.","volume":"15","author":"W Checkley","year":"2015","journal-title":"Lancet Infect Dis."},{"key":"ref-2","doi-asserted-by":"publisher","first-page":"S232-45","DOI":"10.1093\/cid\/cis753","article-title":"The Global Enteric Multicenter Study (GEMS) of diarrheal disease in infants and young children in developing countries: epidemiologic and clinical methods of the case\/control study.","volume":"55 Suppl 4","author":"K Kotloff","year":"2012","journal-title":"Clin Infect Dis."},{"key":"ref-3","doi-asserted-by":"publisher","first-page":"555-63","DOI":"10.1097\/QCO.0b013e328357e569","article-title":"Burden of disease from cryptosporidiosis.","volume":"25","author":"D Shirley","year":"2012","journal-title":"Curr Opin Infect Dis."},{"key":"ref-4","doi-asserted-by":"publisher","first-page":"189-91","DOI":"10.1038\/503189a","article-title":"Parasitic infections: Time to tackle cryptosporidiosis.","volume":"503","author":"B Striepen","year":"2013","journal-title":"Nature."},{"key":"ref-5","doi-asserted-by":"publisher","first-page":"837-50","DOI":"10.1016\/j.pcl.2017.03.014","article-title":"Cryptosporidium and Giardia Infections in Children: A Review.","volume":"64","author":"B Mmbaga","year":"2017","journal-title":"Pediatr Clin North Am."},{"key":"ref-6","doi-asserted-by":"publisher","first-page":"220-7","DOI":"10.1093\/infdis\/jix294","article-title":"Etiology of Severe Acute Watery Diarrhea in Children in the Global Rotavirus Surveillance Network Using Quantitative Polymerase Chain Reaction.","volume":"216","author":"D Operario","year":"2017","journal-title":"J Infect Dis."},{"key":"ref-7","doi-asserted-by":"publisher","first-page":"ciy355","DOI":"10.1093\/cid\/ciy355","article-title":"Epidemiology and Risk Factors for Cryptosporidiosis in Children from Eight Low-income Sites: Results from the MAL-ED Study.","author":"P Korpe","year":"2018","journal-title":"Clin Infect Dis."},{"key":"ref-8","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1186\/1471-2334-9-195","article-title":"High dose prolonged treatment with nitazoxanide is not effective for cryptosporidiosis in HIV positive Zambian children: a randomised controlled trial.","volume":"9","author":"B Amadi","year":"2009","journal-title":"BMC Infect Dis."},{"key":"ref-9","doi-asserted-by":"publisher","first-page":"494-9","DOI":"10.1097\/QCO.0b013e32833de052","article-title":"Treatment of cryptosporidiosis: do we know what we think we know?","volume":"23","author":"M Cabada","year":"2010","journal-title":"Curr Opin Infect Dis."},{"key":"ref-10","doi-asserted-by":"publisher","first-page":"387-93","DOI":"10.1111\/j.1365-2125.2007.02873.x","article-title":"Treatment of cryptosporidiosis in immunocompromised individuals: systematic review and meta-analysis.","volume":"63","author":"I Abubakar","year":"2007","journal-title":"Br J Clin Pharmacol."},{"key":"ref-11","doi-asserted-by":"publisher","first-page":"CD004932","DOI":"10.1002\/14651858.CD004932.pub2","article-title":"Prevention and treatment of cryptosporidiosis in immunocompromised patients.","author":"I Abubakar","year":"2007","journal-title":"Cochrane Database Syst Rev."},{"key":"ref-12","doi-asserted-by":"publisher","first-page":"530-7","DOI":"10.1021\/acsinfecdis.6b00094","article-title":"Cryptosporidiosis Drug Discovery: Opportunities and Challenges.","volume":"2","author":"U Manjunatha","year":"2016","journal-title":"ACS Infect Dis."},{"key":"ref-13","doi-asserted-by":"publisher","first-page":"201-8","DOI":"10.2217\/17460913.1.2.201","article-title":"Molecular basis of Cryptosporidium-host cell interactions: recent advances and future prospects.","volume":"1","author":"J Wanyiri","year":"2006","journal-title":"Future Microbiol."},{"key":"ref-14","doi-asserted-by":"publisher","first-page":"390-400","DOI":"10.1128\/CMR.15.3.390-400.2002","article-title":"In vitro cultivation of cryptosporidium species.","volume":"15","author":"M Arrowood","year":"2002","journal-title":"Clin Microbiol Rev."},{"key":"ref-15","doi-asserted-by":"publisher","first-page":"1231-42","DOI":"10.1016\/j.ijpara.2011.08.001","article-title":"Evolution of Cryptosporidium in vitro culture.","volume":"41","author":"P Karanis","year":"2011","journal-title":"Int J Parasitol."},{"key":"ref-16","doi-asserted-by":"publisher","first-page":"1996-2001","DOI":"10.1128\/IAI.01131-12","article-title":"Human primary intestinal epithelial cells as an improved in vitro model for Cryptosporidium parvum infection.","volume":"81","author":"A Castellanos-Gonzalez","year":"2013","journal-title":"Infect Immun."},{"key":"ref-17","doi-asserted-by":"publisher","first-page":"99-107","DOI":"10.1128\/IAI.74.1.99-107.2006","article-title":"Interaction of Cryptosporidium hominis and Cryptosporidium parvum with primary human and bovine intestinal cells.","volume":"74","author":"A Hashim","year":"2006","journal-title":"Infect Immun."},{"key":"ref-18","doi-asserted-by":"publisher","first-page":"47-54","DOI":"10.1016\/j.mimet.2014.07.017","article-title":"A new in vitro model using small intestinal epithelial cells to enhance infection of Cryptosporidium parvum.","volume":"106","author":"E Varughese","year":"2014","journal-title":"J Microbiol Methods."},{"key":"ref-19","doi-asserted-by":"publisher","first-page":"1-26","DOI":"10.1007\/s10565-005-0085-6","article-title":"The Caco-2 cell line as a model of the intestinal barrier: Influence of cell and culture-related factors on Caco-2 cell functional characteristics.","volume":"21","author":"Y Sambuy","year":"2005","journal-title":"Cell Biol Toxicol."},{"key":"ref-20","doi-asserted-by":"publisher","first-page":"367-73","DOI":"10.1016\/j.ijpara.2015.01.009","article-title":"New developments in Cryptosporidium research.","volume":"45","author":"U Ryan","year":"2015","journal-title":"Int J Parasitol."},{"key":"ref-21","doi-asserted-by":"publisher","first-page":"749-61","DOI":"10.1017\/S0031182016000275","article-title":"The fine structure of sexual stage development and sporogony of Cryptosporidium parvum in cell-free culture.","volume":"143","author":"H Aldeyarbi","year":"2016","journal-title":"Parasitology."},{"key":"ref-22","doi-asserted-by":"publisher","first-page":"21-9","DOI":"10.1016\/j.ijpara.2015.07.006","article-title":"Continuous culture of Cryptosporidium parvum using hollow fiber technology.","volume":"46","author":"M Morada","year":"2016","journal-title":"Int J Parasitol."},{"key":"ref-23","doi-asserted-by":"publisher","first-page":"197-201","DOI":"10.1016\/j.ijpara.2017.10.001","article-title":"A cell culture platform for Cryptosporidium that enables long-term cultivation and new tools for the systematic investigation of its biology.","volume":"48","author":"C Miller","year":"2018","journal-title":"Int J Parasitol."},{"key":"ref-24","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.00731-16","article-title":"Novel Bioengineered Three-Dimensional Human Intestinal Model for Long-Term Infection of Cryptosporidium parvum.","volume":"85","author":"M DeCicco RePass","year":"2017","journal-title":"Infect Immun."},{"key":"ref-25","doi-asserted-by":"publisher","first-page":"13708","DOI":"10.1038\/srep13708","article-title":"Robust bioengineered 3D functional human intestinal epithelium.","volume":"5","author":"Y Chen","year":"2015","journal-title":"Sci Rep."},{"key":"ref-26","doi-asserted-by":"publisher","first-page":"5167-75","DOI":"10.1128\/IAI.68.9.5167-5175.2000","article-title":"Mediation of Cryptosporidium parvum infection in vitro by mucin-like glycoproteins defined by a neutralizing monoclonal antibody.","volume":"68","author":"A Cevallos","year":"2000","journal-title":"Infect Immun."},{"key":"ref-27","doi-asserted-by":"publisher","first-page":"e0187880","DOI":"10.1371\/journal.pone.0187880","article-title":"In vitro enteroid-derived three-dimensional tissue model of human small intestinal epithelium with innate immune responses.","volume":"12","author":"Y Chen","year":"2017","journal-title":"PLoS One."},{"key":"ref-28","doi-asserted-by":"publisher","first-page":"633-42","DOI":"10.1038\/nrgastro.2016.142","article-title":"Human mini-guts: new insights into intestinal physiology and host-pathogen interactions.","volume":"13","author":"J In","year":"2016","journal-title":"Nat Rev Gastroenterol Hepatol."},{"key":"ref-29","doi-asserted-by":"publisher","first-page":"3759-66","DOI":"10.1074\/jbc.R114.635995","article-title":"Human Enteroids\/Colonoids and Intestinal Organoids Functionally Recapitulate Normal Intestinal Physiology and Pathophysiology.","volume":"291","author":"N Zachos","year":"2016","journal-title":"J Biol Chem."},{"key":"ref-30","article-title":"Novel bioengineered 3D in vitro and ex-vivo human intestinal models for long term infection of Cryptosporidium spp","author":"M DiCicco RePass"},{"key":"ref-31","doi-asserted-by":"publisher","DOI":"10.14814\/phy2.13060","article-title":"Cryptosporidium parvum infection attenuates the ex vivo propagation of murine intestinal enteroids.","volume":"4","author":"X Zhang","year":"2016","journal-title":"Physiol Rep."},{"key":"ref-32","doi-asserted-by":"publisher","first-page":"814-23","DOI":"10.1038\/s41564-018-0177-8","article-title":"Modelling Cryptosporidium infection in human small intestinal and lung organoids.","volume":"3","author":"I Heo","year":"2018","journal-title":"Nat Microbiol."},{"key":"ref-33","doi-asserted-by":"publisher","first-page":"477-80","DOI":"10.1038\/nature14651","article-title":"Genetic modification of the diarrhoeal pathogen Cryptosporidium parvum.","volume":"523","author":"S Vinayak","year":"2015","journal-title":"Nature."},{"key":"ref-34","doi-asserted-by":"publisher","first-page":"441-5","DOI":"10.1126\/science.1094786","article-title":"Complete genome sequence of the apicomplexan, Cryptosporidium parvum.","volume":"304","author":"M Abrahamsen","year":"2004","journal-title":"Science."},{"key":"ref-35","doi-asserted-by":"publisher","first-page":"1107-12","DOI":"10.1038\/nature02977","article-title":"The genome of Cryptosporidium hominis.","volume":"431","author":"P Xu","year":"2004","journal-title":"Nature."},{"key":"ref-36","doi-asserted-by":"publisher","first-page":"1307-14","DOI":"10.1093\/infdis\/jiv588","article-title":"Preassembled Single-Stranded RNA-Argonaute Complexes: A Novel Method to Silence Genes in Cryptosporidium.","volume":"213","author":"A Castellanos-Gonzalez","year":"2016","journal-title":"J Infect Dis."},{"key":"ref-37","doi-asserted-by":"publisher","first-page":"867-74","DOI":"10.1016\/j.ijpara.2017.05.002","article-title":"Targeted gene knockdown validates the essential role of lactate dehydrogenase in Cryptosporidium parvum.","volume":"47","author":"W Witola","year":"2017","journal-title":"Int J Parasitol."},{"key":"ref-38","doi-asserted-by":"publisher","first-page":"649-56","DOI":"10.1016\/j.ijpara.2018.01.005","article-title":"Morpholino-mediated in vivo silencing of Cryptosporidium parvum lactate dehydrogenase decreases oocyst shedding and infectivity.","volume":"48","author":"X Zhang","year":"2018","journal-title":"Int J Parasitol."},{"key":"ref-39","doi-asserted-by":"publisher","first-page":"413-4","DOI":"10.1038\/nature14636","article-title":"Parasitology: CRISPR for Cryptosporidium.","volume":"523","author":"S Beverley","year":"2015","journal-title":"Nature."},{"key":"ref-40","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1186\/s13071-018-2754-3","article-title":"Transcriptome analysis of pig intestinal cell monolayers infected with Cryptosporidium parvum asexual stages.","volume":"11","author":"M Mirhashemi","year":"2018","journal-title":"Parasit Vectors."},{"key":"ref-41","doi-asserted-by":"publisher","first-page":"413-22","DOI":"10.1016\/j.ijpara.2017.10.007","article-title":"RNA-Seq analysis during the life cycle of Cryptosporidium parvum reveals significant differential gene expression between proliferating stages in the intestine and infectious sporozoites.","volume":"48","author":"C Lippuner","year":"2018","journal-title":"Int J Parasitol."},{"key":"ref-42","doi-asserted-by":"publisher","first-page":"662-4","DOI":"10.1016\/j.pt.2017.07.004","article-title":"New Tools for Cryptosporidium Lead to New Hope for Cryptosporidiosis.","volume":"33","author":"H Ward","year":"2017","journal-title":"Trends Parasitol."},{"key":"ref-43","doi-asserted-by":"publisher","first-page":"376-80","DOI":"10.1038\/nature22337","article-title":"A Cryptosporidium PI(4)K inhibitor is a drug candidate for cryptosporidiosis.","volume":"546","author":"U Manjunatha","year":"2017","journal-title":"Nature."},{"key":"ref-44","doi-asserted-by":"publisher","first-page":"1856-64","DOI":"10.1093\/infdis\/jiw488","article-title":"Novel Bumped Kinase Inhibitors Are Safe and Effective Therapeutics in the Calf Clinical Model for Cryptosporidiosis.","volume":"214","author":"D Schaefer","year":"2016","journal-title":"J Infect Dis."},{"key":"ref-45","doi-asserted-by":"publisher","first-page":"753-63","DOI":"10.1016\/j.ijpara.2017.08.006","article-title":"Advances in bumped kinase inhibitors for human and animal therapy for cryptosporidiosis.","volume":"47","author":"M Hulverson","year":"2017","journal-title":"Int J Parasitol."},{"key":"ref-46","doi-asserted-by":"publisher","first-page":"1275-84","DOI":"10.1093\/infdis\/jix120","article-title":"Bumped-Kinase Inhibitors for Cryptosporidiosis Therapy.","volume":"215","author":"M Hulverson","year":"2017","journal-title":"J Infect Dis."},{"key":"ref-47","doi-asserted-by":"publisher","first-page":"pii: e00147-18","DOI":"10.1128\/AAC.00147-18","article-title":"Therapeutic Efficacy of Bumped Kinase Inhibitor 1369 in a Pig Model of Acute Diarrhea Caused by Cryptosporidium hominis.","volume":"62","author":"S Lee","year":"2018","journal-title":"Antimicrob Agents Chemother."},{"key":"ref-48","doi-asserted-by":"publisher","first-page":"e1005763","DOI":"10.1371\/journal.ppat.1005763","article-title":"Open Source Drug Discovery with the Malaria Box Compound Collection for Neglected Diseases and Beyond.","volume":"12","author":"W Van Voorhis","year":"2016","journal-title":"PLoS Pathog."},{"key":"ref-49","doi-asserted-by":"publisher","first-page":"pii: e01505-17","DOI":"10.1128\/AAC.01505-17","article-title":"A Novel Piperazine-Based Drug Lead for Cryptosporidiosis from the Medicines for Malaria Venture Open-Access Malaria Box.","volume":"62","author":"R Jumani","year":"2018","journal-title":"Antimicrob Agents Chemother."},{"key":"ref-50","doi-asserted-by":"publisher","first-page":"e0006183","DOI":"10.1371\/journal.pntd.0006183","article-title":"Clinical and microbiologic efficacy of the piperazine-based drug lead MMV665917 in the dairy calf cryptosporidiosis model.","volume":"12","author":"E Stebbins","year":"2018","journal-title":"PLoS Negl Trop Dis."},{"key":"ref-51","doi-asserted-by":"publisher","first-page":"43-9","DOI":"10.1016\/j.ijpddr.2018.01.003","article-title":"Discovery of ebselen as an inhibitor of Cryptosporidium parvum glucose-6-phosphate isomerase (CpGPI) by high-throughput screening of existing drugs.","volume":"8","author":"R Eltahan","year":"2018","journal-title":"Int J Parasitol Drugs Drug Resist."},{"key":"ref-52","doi-asserted-by":"publisher","first-page":"pii: e00124-18","DOI":"10.1128\/mSphere.00124-18","article-title":"Monoclonal Antibodies to Intracellular Stages of Cryptosporidium parvum Define Life Cycle Progression In Vitro.","volume":"3","author":"G Wilke","year":"2018","journal-title":"mSphere."},{"key":"ref-53","doi-asserted-by":"publisher","first-page":"401-2","DOI":"10.1016\/j.pt.2015.08.003","article-title":"Cryptosporidium: a first step toward tractability.","volume":"31","author":"L Hedstrom","year":"2015","journal-title":"Trends Parasitol."}],"container-title":["F1000Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/f1000research.com\/articles\/7-1380\/v1\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/f1000research.com\/articles\/7-1380\/v1\/pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/f1000research.com\/articles\/7-1380\/v1\/iparadigms","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,3,29]],"date-time":"2019-03-29T19:31:53Z","timestamp":1553887913000},"score":1,"resource":{"primary":{"URL":"https:\/\/f1000research.com\/articles\/7-1380\/v1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,3]]},"references-count":53,"URL":"https:\/\/doi.org\/10.12688\/f1000research.15333.1","relation":{"has-review":[{"id-type":"doi","id":"10.5256\/f1000research.16706.r37850","asserted-by":"subject"},{"id-type":"doi","id":"10.5256\/f1000research.16706.r37851","asserted-by":"subject"},{"id-type":"doi","id":"10.5256\/f1000research.16706.r37849","asserted-by":"subject"}]},"ISSN":["2046-1402"],"issn-type":[{"value":"2046-1402","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,3]]},"assertion":[{"value":"Indexed","URL":"https:\/\/f1000research.com\/articles\/7-1380\/v1#article-reports","order":0,"name":"referee-status","label":"Referee status","group":{"name":"current-referee-status","label":"Current Referee Status"}},{"value":"10.5256\/f1000research.16706.r37850, Xian-Ming Chen, Department of Medical Microbiology and Immunology, Creighton University School of Medicine, Omaha, USA, 03 Sep 2018, version 1, indexed","URL":"https:\/\/f1000research.com\/articles\/7-1380\/v1#referee-response-37850","order":0,"name":"referee-response-37850","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"10.5256\/f1000research.16706.r37851, Boris Striepen, Elizabeth English, Department of Pathobiology, University of Pennsylvania, Philadelphia, USA, 03 Sep 2018, version 1, indexed","URL":"https:\/\/f1000research.com\/articles\/7-1380\/v1#referee-response-37851","order":1,"name":"referee-response-37851","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"10.5256\/f1000research.16706.r37849, Robin Gasser, Melbourne Veterinary School, Department of Veterinary Biosciences, Faculty of Veterinary and Agricultural Sciences, The University of Melbourne, Parkville, Australia, 03 Sep 2018, version 1, indexed","URL":"https:\/\/f1000research.com\/articles\/7-1380\/v1#referee-response-37849","order":2,"name":"referee-response-37849","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"The author(s) declared that no grants were involved in supporting this work","order":3,"name":"grant-information","label":"Grant Information"},{"value":"This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.","order":0,"name":"copyright-info","label":"Copyright"}]}}